VINCENT TAM to Bacteremia
This is a "connection" page, showing publications VINCENT TAM has written about Bacteremia.
Connection Strength
3.752
-
Clinical and genomic analysis of virulence-related genes in bloodstream infections caused by Acinetobacter baumannii. Virulence. 2022 Dec; 13(1):1920-1927.
Score: 0.602
-
Real life experience with ceftolozane/tazobactam therapy for Pseudomonas aeruginosa bacteremia. J Chemother. 2021 Dec; 33(8):595-597.
Score: 0.533
-
Outcomes of empiric aminoglycoside monotherapy for Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2019 Apr; 93(4):346-348.
Score: 0.454
-
Impact of hyperglycemia on outcomes of patients with Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2016 Feb; 84(2):155-8.
Score: 0.368
-
A model to predict mortality following Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis. 2012 Jan; 72(1):97-102.
Score: 0.279
-
Pharmacokinetics of polymyxin B in an infant with multidrug-resistant Klebsiella pneumoniae bacteremia. Pediatr Infect Dis J. 2011 Jun; 30(6):537-9.
Score: 0.271
-
Prevalence, resistance mechanisms, and susceptibility of multidrug-resistant bloodstream isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010 Mar; 54(3):1160-4.
Score: 0.247
-
Prevalence of type III secretion protein exoenzymes and antimicrobial susceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa bacteremia. J Chemother. 2008 Dec; 20(6):714-20.
Score: 0.228
-
Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis. 2008 Mar 15; 46(6):862-7.
Score: 0.217
-
Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2007 Jul; 58(3):309-14.
Score: 0.207
-
Prevalence of AmpC over-expression in bloodstream isolates of Pseudomonas aeruginosa. Clin Microbiol Infect. 2007 Apr; 13(4):413-8.
Score: 0.203
-
Ceftolozane/tazobactam activity against meropenem-non-susceptible Pseudomonas aeruginosa bloodstream infection isolates. J Glob Antimicrob Resist. 2017 12; 11:154-155.
Score: 0.106
-
Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center. Clin Infect Dis. 2002 Apr 01; 34(7):922-9.
Score: 0.036